Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.57 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | RARB | P10826 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.57 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818028 | 1.00 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL480331 | 1.00 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| Carbamic Acid SCHEMBL9949842 | 0.96 | PTGS2 (0.57) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| Nitric Acid SCHEMBL28366794 | 0.89 | PTGS2 (0.50) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL59197 | 0.88 | PTGS2 (0.74) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL13992556 | 0.86 | PTGS2 (0.45) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL6551674 | 0.86 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL4651605 | 0.86 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL27513027 | 0.84 | EPHX1 (0.42) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL14511593 | 0.83 | PTGS2 (0.42) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346841-B1 | 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ S P A (IT) | 2015-01-14 | — | — | EP | disclosed |
| US-8624036-B2 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2014-01-07 | — | — | US | disclosed |
| WO-2010031835-A2 | 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2010-03-25 | — | — | WO | disclosed |
| EP-2166006-A1 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them | Dompe' S.P.A. (IT) | 2010-03-24 | — | — | EP | disclosed |
| EP-2166006-A1 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them | Dompe' S.P.A. (IT) | 2010-03-24 | — | — | EP | disclosed |
| CN-1286835-C | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2006-11-29 | — | — | CN | disclosed |
| EP-1724270-A2 | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | Pfizer Italia S.r.l. (IT) | 2006-11-22 | — | — | EP | disclosed |
| EP-1406899-B1 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2006-11-15 | — | — | EP | disclosed |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | disclosed |
| CN-1531535-A | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | — | 2004-09-22 | — | — | CN | disclosed |
| EP-1406899-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | disclosed |
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-01-29 | — | — | US | disclosed |
| EP-1345909-A1 | PHENYLACETAMIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003008365-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2003-01-30 | — | — | WO | disclosed |
| US-6455559-B1 | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-09-24 | — | — | US | disclosed |
| WO-2002048114-A1 | PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | CDK2, CDK1, CDKN1A | PTGS2 2059/4885PTGS1 1189/4885AKR1C3 833/4885 |
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | DCK, CCNK, CDK2 | PTGS2 2574/4885PTGS1 1950/4885AKR1C3 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.